Without a preventive vaccine, hepatitis C virus (HCV) remains an important pathogen worldwide with millions of carriers at risk of end-stage liver diseases. Despite the introduction of novel direct-acting antivirals (DAAs), resistance problems, challenges with the difficult-to-treat populations and high costs limit the widespread application of these drugs. Antivirals with alternative mechanism(s) of action, such as by restricting viral entry or cell-to-cell spread, could help expand the scope of antiviral strategies for the management of hepatitis C. Transfusion-associated HCV infection remains another issue in endemic and resource-limited areas around the world. This chapter describes some of the latest developments in antiviral strategies to preclude HCV entry, such as through monoclonal antibodies and small molecules, as well as measures to enhance the safety of therapeutic plasma products in blood transfusion.
Original languageEnglish
Title of host publicationAdvances in Treatment of Hepatitis C and B
ISBN (Electronic)978-953-51-2994-3
ISBN (Print)978-953-51-2993-6
Publication statusPublished - Mar 8 2017


  • hepatitis C virus
  • viral entry
  • antivirals
  • entry inhibitors
  • monoclonal antibodies
  • small molecules
  • therapeutic plasma products


Dive into the research topics of 'Strategies to Preclude Hepatitis C Virus Entry'. Together they form a unique fingerprint.

Cite this